Abstract: A bone cap (100) for preventing leakage of medullary canal components in a residual limb (102) that can lead to pathologies such as heterotopic ossification reducing heterotopic ossification and a method for using the same are provided. The bone cap (100) includes a proximal base (114) and an insertion extension portion (116) extending from the proximal base (114). The insertion extension portion (116) has an outer surface and a distal end (112b) opposite the proximal base (114). The insertion extension portion (116) is configured to be inserted into a resected portion of a bone (104) of a patient. The bone cap (100) also has at least one bone engaging feature (120) disposed on the outer surface of the insertion extension portion (116) adjacent to the distal end (112b) of the insertion extension portion (116). A porous coating (122) is disposed on the outer surface of the insertion extension portion (116) adjacent to the proximal base (114).

Abstract: Methods and devices for removing non-viable tissue at a treatment situs are described. The method can include administering a selective biofilm stain dye to the treatment situs at a dilution that selectively stains non-viable tissue compared to viable tissue at a selectivity ratio that provides a visually identifiable separation between the non-viable tissue and the viable tissue. The selective biofilm stain dye is diluted in water to a concentration of from about 0.001 mg/mL to about 0.5 mg/mL. The method can also include visually identifying the non-viable tissue, and removing the non-viable tissue based on the visual identification. A biofilm staining device can include an applicator having a dispense tip, a rupture lever adapted to rupture a rupturable capsule and release a selective biofilm stain dye, and a housing sized to retain the rupturable capsule and adapted to allow released selective biofilm stain dye to flow to the dispense tip.

Abstract: A biofilm reactor substrate support system can comprise a base holder shaped to retain a reactor vessel and comprising a magnetic alignment feature. The biofilm reactor substrate can also comprise a set of reactor racks including a complementary magnetic alignment feature which can be magnetically coupleable to the magnetic alignment feature so as to anchor the base holder and the set of reactor racks in a fixed position relative to one another. Each reactor rack can be coupleable to at least one removable biofilm support microstructure.

Abstract: A medical device that includes a coating of a composite material that includes a polymeric material having a void structure and particulate ceragenin material (i.e., ceragenin particles) associated with the void structure. The average particle size of the ceragenin particles in the composite is in a range from 5 nm to 20 ?m, 50 nm to 10 ?m, 100 nm to 5 ?m, or 1 ?m to 10 ?m. The composite has a high loading of ceragenin particles (e.g., about 10% to about 25%, by weight). The composite has good polymer stability, the ability to release ceragenins from the ceragenin particles disposed in the composite over a sustained period of time at a characteristic elution rate, and the ability to kill large numbers of bacteria and other susceptible microbes over the sustained period of time.

Abstract: A medical device that includes a coating of a composite material that includes a polymeric material having a void structure and particulate ceragenin material (i.e., ceragenin particles) associated with the void structure. The average particle size of the ceragenin particles in the composite is in a range from 5 nm to 20 ?m, 50 nm to 10 ?m, 100 nm to 5 ?m, or 1 ?m to 10 ?m. The composite has a high loading of ceragenin particles (e.g., about 10% to about 25%, by weight). The composite has good polymer stability, the ability to release ceragenins from the ceragenin particles disposed in the composite over a sustained period of time at a characteristic elution rate, and the ability to kill large numbers of bacteria and other susceptible microbes over the sustained period of time.

Abstract: An osseointegrated implant for an amputee includes a surgically implanted post-shaped orthopedic implant rigidly supported by patient bone, wherein the implant protrudes through overlying stump tissue to an external location for suitable attachment to a prosthetic limb or the like. A non-invasive electrical stimulation system provides controlled electrical stimulation at the implant-bone interface for achieving rapid and secure fixation by osseointegration in a significantly reduced rehabilitation time. The electrical stimulation system utilizes at least one and preferably multiple electrodes mounted externally onto the patient in close proximity to the implant-bone interface, with an external portion of the implant providing a second electrode. In one preferred form, the implant comprises a base structure of titanium or titanium alloy or the like, coated with a thin film of a highly conductive substance such as gold for improved electrical conductivity.